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95Purpose: Prospective studies on the effect of dexamethasone after microvascular reconstructive head
and neck surgery are sparse despite the widespread use of dexamethasone in this setting. The aim of
this study was to clarify whether perioperative use of dexamethasone would improve the quality and
speed of recovery. The authors hypothesized that dexamethasone would enhance recovery and diminish
pain and nausea.
Materials and Methods: Ninety-three patients with oropharyngeal cancer and microvascular recon-
struction were included in this prospective double-blinded randomized controlled trial. Patients in the
study group (n = 51) received dexamethasone 60 mg over 3 perioperative days; 42 patients did not receive
dexamethasone and served as controls. Patient rehabilitation, postoperative opioid and insulin consump-
tion, postoperative nausea and vomiting (PONV), and C-reactive protein (CRP), leukocyte, and lactate
levels were recorded.
Results: There was significantly less pain in the study group (P = .030) and the total oxycodone dose for
5 days postoperatively was lower (P = .040). Dexamethasone did not significantly lessen PONV for 5 days
postoperatively (P > .05). There were no differences between groups in intensive care unit or hospital
stay or in other clinical measures of recovery. Patients receiving dexamethasone required significantly
more insulin compared with patients in the control group (P < .001). Lactate and leukocyte levels were
significantly higher (P < .001) and CRP levels were significantly lower in the study group.
Conclusion: The only benefit of perioperative dexamethasone use was lower total oxycodone dose;
however, the disadvantages were greater. Because dexamethasone can have adverse effects on theltant, Department of Oral and Maxillofacial Surgery,
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173postoperative course, routine use of dexamethasone as a pain or nausea medication during reconstructive
head and neck cancer surgery is not recommended.
 2018 Published by Elsevier Inc. on behalf of the American Association of Oral and Maxillofacial
Surgeons
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224Malignant tumors of the head and neck area usually
require microvascular reconstruction to repair the
surgical defect. Patients often need a tracheostomy,
and major postoperative swelling problems are com-
mon related side effects from major surgery. Intensive
care unit (ICU) and hospital treatment periods are
usually long, and anatomically demanding surgery
causes major morbidity.1-3 Primary healing without
postoperative complications is an important goal for
surgeons and patients. Prolonged periods of
treatment often aggravate postoperative problems
and can delay possible adjuvant oncologic treatments.
After a wide variety of surgical procedures,
including reconstructive surgery, glucocorticoids
(GCs) are given to patients to relieve postoperative
pain, swelling, and postoperative nausea and vomiting
(PONV), although the evidence of benefit in postoper-
ative use is contentious.4-10 In reconstructive head
and neck cancer surgery, GCs also are believed to
lower the risk of complications, such as prolonged
intubation and sedation, and prevent edema in
the area of the anastomosis and possible flap
loss, thus improving patient recovery. However, even
short-term (<1-week) GC use can cause severe
complications,11-14 wound-healing problems, and
postoperative infections.15-17 In their previous study,
the authors reported that major complications
occurred more frequently in patients administered
GCs than in the control group (P = .012). In
addition, all infections that required surgical
intervention within 3 weeks of the operation
occurred in patients receiving dexamethasone.18
PONV is a common complication after anesthesia
and surgery. Emetic episodes can cause numerous
complications, such as gastric aspiration, wound
dehiscence, psychological distress, and delayed recov-
ery and discharge times.19 Especially in reconstructive
head and neck surgery, PONV can jeopardize primary
healing of the reconstructed area.
The most common complication of GC treatment
is an increase in serum glucose concentrations.
Increased glucose levels also are believed to influence
infections and wound healing. Lactate is a marker of
anaerobic metabolism and of perfusion adequacy.
Hyperglycemia and hyperlactatemia are associated
with increased mortality and are predictors of clinical
outcome in patients requiring intensive care.20-22 Little
has been published on the influence of steroids on
lactate levels.FLA 5.5.0 DTD  YJOMS58278_proof The aims of this study were to clarify the effects of
dexamethasone on quality and speed of recovery,
pain, PONV, lactate levels, and need for insulin after
surgery of patients with microvascular reconstruction
for head and neck cancer. The authors hypothesized
that dexamethasone would enhance recovery and
diminish pain and nausea.Materials and Methods
The authors conducted a prospective randomized
double-blinded controlled trial involving adult patients
with head and neck cancer undergoing reconstructive
surgery. The study was performed from December
2008 through February 2013 in the Departments of
Oral and Maxillofacial Surgery and Plastic Surgery of
the Helsinki University Hospital (Helsinki, Finland).
This study followed the Declaration of Helsinki on
medical protocol and ethics, and the regional ethical
review board of the Helsinki University Central Hospi-
tal approved the study. The study was registered with
EudraCT (number 2008-000892-11). Written informed
consent was obtained from all patients before
randomization.
A total of 110 consecutive patients with oropharyn-
geal cancer who underwent surgery with microvas-
cular reconstruction were included. Patients with
the following characteristics were excluded: a history
of liver or kidney dysfunction, glaucoma, peptic ulcer,
psychosis from the use of steroids, allergy to any
constituent of the dexamethasone preparation used
(DXM sodium phosphate; Oradexon, N.V. Organon,
Netherlands), steroid medication for other diseases,
or non-provision of written informed consent.
Patients were randomized into 2 groups; one
received perioperative and postoperative dexametha-
sone (DEX group) and the other did not receive any
steroids (controls; NON-DEX group). In the DEX
group, patients received dexamethasone 10 mg intra-
venously (IV) during the induction of anesthesia
followed by subsequent 10-mg doses every 8 hours
on the first day, every 12 hours on the second day,
and 1 dose on the third day (total, 60 mg). In the
NON-DEX group, patients did not receive dexametha-
sone. Randomization was performed using sealed
envelopes by a person not otherwise involved in the
study. The information on which patients would
receive dexamethasone was provided in a sealed enve-
lope to the attending anesthesiologist of the operation.1 June 2018  10:29 am  CE AH
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336The same anesthesiologist administered all doses to
the patient during the operation and in the ICU post-
operatively. Surgeons were unaware of the group to
which patients were assigned. The information of
the group was not given to the surgeons at any stage
during the patient’s treatment.
All patients were evaluated by the multidisciplinary
head and neck tumor board at the Helsinki University
Hospital and were assessed to require free flap recon-
struction. Baseline data included demographics, med-
ical history, and information of possible preoperative
and postoperative chemotherapy or radiotherapy.
Most tumors (92%) were squamous cell carcinomas.
There were 83 fasciocutaneous and 10 osteofasciocu-
taneus reconstructions. Groups were similar in locali-
zations. The radial forearm was the most frequent flap
used (n = 51), followed by the anterolateral thigh flap
(n = 32). A detailed description of preoperative medi-
cal data, surgical data, TNM classifications, parameters
during surgery, and complications rated can be found
in the authors’ previous study.18
Surgery was performed under standard balanced
anesthesia. Patients were given antibiotics targeted
for 7 days, starting with cefuroxime 1.5 g  3 IV and
metronidazole 500mg 1 3 IVon induction of general
anesthesia. For allergies, clindamycin 300 mg  4 IV
was given. All patients were admitted to the ICU after
microvascular reconstruction for the immediate recov-
ery phase. Patients were sedated with a continuous
infusion of propofol and alfentanil. After stabilization
and verification of the vitality of the microvascular
flap, sedation was discontinued and the patient was
weaned from the respirator. C-reactive protein
(CRP), leukocyte, glucose, and lactate levels were
measured for 5 days postoperatively. The targeted
glucose level was 5 to 8 mmol/L and was maintained
with insulin infusion; consumption was registered.
The total daily amount of insulin was recorded.
Pain was measured using a 10-cm visual analog scale
(VAS) of nursing verbal pain scores from 0 (no pain) to
10 (maximumpain) every time before painmedication
was administered. All patients received paracetamol
1 g 3 IVand postoperative pain was controlled using
only oxycodone 0.2 to 0.4 mg/10 kg IV. Oxycodone
was given if the VAS score was higher than 3. PONV
was evaluated whenever patients had severe nausea.
The degree of nausea was difficult to grade because
of the severity of these operations and most patients
were sedated or unable to speak for a long time after
surgery. Ondansetron 4 mg IV was administered for
PONV if severe retching occurred.
Postoperative data were collected on length of
sedation (as duration of propofol infusion), opioid
infusion, and intravenous antibiotics. The need for
oxycodone and antiemetics was recorded for 5 days
postoperatively. Patient rehabilitation (ability to sit,FLA 5.5.0 DTD  YJOMS58278_proof stand, walk, and drink fluids) was recorded. Patients
were followed for 30 days after surgery for any surgical
or medical complications. Data from the follow-up
forms and hospital database were collected and sorted
by 1 clinician (S.K.; Table 1).
STATISTICAL ANALYSIS
The relevance of associations between groups and
categorical variables was evaluated by c2 tests and
differences in mean values between groups and
continuous variables were evaluated by Wilcoxon
2-sample tests. Differences in pain measured by the
VAS and levels of insulin, lactate, and CRP area under
the curve (VAS AUC) between groups were assessed
by logistic regression.
Results
RECOVERY
Ninety-seven patients met the inclusion criteria for
the study; 4 patients were excluded. Three patients
did not need free flap reconstruction and 1 was acci-
dentally administrated additional dexamethasone.
Therefore, the total number of patients included was
93. Of these, 73 were from the department of maxillo-
facial surgery and 20 were from the department of
plastic surgery. There were 51 patients in the DEX
group and 42 patients in the NON-DEX group. The
size discrepancy between the 2 groups is explained
by chance of randomization. No relevant differences
were noted in the demographic data between the 2
groups. More patients with diabetes were in the DEX
group; this difference was not statistically significant
(P = .116). There were no differences between groups
in parameters of postoperative mobilization or ability
to drink fluids after surgery. There also were no rele-
vant differences in the length of ICU and hospital
stay between groups (Table 1).
PAIN
The total oxycodone dose for 5 days postoperatively
was significantly lower in the DEX group than in the
NON-DEX group (P = .040; Table 1). Patients in the
DEX group reported significantly less pain (P = .030)
as assessed by the mean VAS AUC measured 7 days
postoperatively. The most notable difference in
pain was observed during the first postoperative
day (Fig 1).
POSTOPERATIVE NAUSEA AND VOMITING
PONVoccurred in 18 patients (19%) for 5 days post-
operatively. Six patients in the DEX group (12%)
received a total dose of ondansetron of 34 mg (4
patients received 1 dose and 2 patients received 2
doses); 12 patients in the NON-DEX group (29%)1 June 2018  10:29 am  CE AH
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Table 1. PATIENT CHARACTERISTICS AND POSTOPERATIVE RESULTS
All (N = 93) DEX (n = 51) NON-DEX (n = 42) P Value
Age (yr) 65 (34-93) 65 (39-93) 65 (34-88) .798
Male/female 59/34 32/19 27/15 .878
CCI, 0-1/2-4/5-9 49/29/15 24/19/8 25/10/7 .363
Diabetes 15 of 93 (18%) 11 of 51 (22%) 4 of 42 (10%) .116
Operation time (minutes) 340 (87-975) 340 (138-975) 359 (208-719) .373
Length of ICU stay (days) 3 (1-12) 3 (1-12) 3 (1-8) .965
Length of hospital stay
(days; n = 91)
13 (5-49) 12 (5-35) 13 (6-49) .594
Length of sedation infusion
(days)
2 (0-6) 2 (1-6) 1 (0-6) .088
Length of opioid infusion (days) 1 (0-4) 1 (0-3) 1 (0-4) .497
Total dose of oxycodone in
5 days (mg)
95.2 81.2 112.14 .040*
Total dose of ondansetron in
5 days (mg)
83 (mean 0.89) 34 (mean 0.67) 49 (mean 1.17) .0583
Length of IV antibiotics (days) 7 (3-30) 8 (3-30) 7 (3-22) .209
Able to sit (days) 2 (1-6) 2 (1-6) 2 (1-6) .5174
Able to stand (days) 2 (1-7) 2 (1-6) 2 (1-7) .537
Able to walk (days) 3 (1-12) 3 (1-12) 3 (1-10) .784
Able to drink fluids (days) 4 (1-19) 3 (1-19) 5 (1-17) .171
Note: Data are presented as median (range) unless otherwise indicated.
Abbreviations: CCI, Charlson Comorbidity Index; DEX, dexamethasone group; ICU, intensive care unit; IV, intravenous;
NON-DEX, non-dexamethasone group.
* P < .05 (significant).
Kainulainen et al. Dexamethasone and Postoperative Recovery. J Oral Maxillofac Surg 2018.
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425received a total dose of ondansetron of 49 mg (11
patients received 1 dose and 1 patient received 2
doses; P = .0583; Table 1). The most relevant differ-
ence was on the second postoperative day whenFIGURE 1. VAS area under the curve after microvascular reconstructio
patients with dexamethasone; NON-DEX, patients without dexamethason
Kainulainen et al. Dexamethasone and Postoperative Recovery. J Oral M
FLA 5.5.0 DTD  YJOMS58278_proof patients in the NON-DEX group (6 of 41 patients;
mean, 0.51 mg) received significantly more anti-
emetics compared with the DEX group (1 of 50
patients; mean, 0.08 mg; P = .0264). Informationn, Data are presented as means with 95% confidence limits. DEX,
e; VAS, visual analog scale. Q5
axillofac Surg 2018.
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538was not available from 2 patients (1 in the DEX group
and 1 in the NON-DEX group) on the second day.
GLUCOSE BALANCE
Patients in the DEX group required considerably
more insulin for 6 postoperative days compared with
patients in the NON-DEX group (total insulin needed,
93.5 vs 10.3 U, respectively; P < .001). The greatest
difference was on the second postoperative day
(Fig 2, Table 1).
METABOLIC AND INFLAMMATORY RESPONSE
Data on lactate levels were collected only postoper-
atively. Lactate levels were significantly higher in the
DEX group than in the control group (P < .001) for
the first 5 postoperative days (Fig 3). CRP levels
were significantly lower (P < .001) and leukocyte
counts were significantly higher (P < .001) in the
DEX group (Figs 4, 5).
Discussion
The present study showed that dexamethasone had
only a minor effect on postoperative healing. Dexa-
methasone use did not decrease the operation time
or the duration of sedation. There was no difference
in the length of ICU or hospital stay or the ability to
sit, stand, walk, or drink fluids between groups. In
their previous study of the same study population,
the authors found that the use of dexamethasone
was associated with more complications, especially
regarding postoperative infections.18
Postoperative pain management relieves suffering,
can accelerate earlier mobilization, and decreaseFIGURE 2. Insulin area under the curve after microvascular reconstructio
patients with dexamethasone; IU, international units of insulin; NON-DEX
Kainulainen et al. Dexamethasone and Postoperative Recovery. J Oral M
FLA 5.5.0 DTD  YJOMS58278_proof hospital stay duration and costs. Many published re-
ports in different surgical fields have described the
analgesic effect of steroids.23-27 In the present study,
patients receiving dexamethasone also reported less
pain and needed less oxycodone for 5 postoperative
days. A study by Clayburgh et al28 showed that
extended perioperative corticosteroid use after transo-
ral robotic surgery for initial treatment of oropharyn-
geal squamous cell carcinoma decreased the length
of hospital stay, although postoperative pain was mini-
mally affected. The present trial is the first prospective
randomized study to evaluate the perioperative use of
dexamethasone in patients with head and neck cancer
andmicrovascular reconstruction. Although the use of
dexamethasone decreased the total amount of analge-
sics and pain, dexamethasone did not accelerate the
healing and recovery process and did not shorten
the hospital stay.
Dexamethasone is widely used by anesthesiologists
to treat PONV. Wattwil et al29 found that ondansetron
and dexamethasone were equally effective in the pre-
vention of PONV after breast surgery. Dexamethasone
did not meaningfully decrease PONV in the studies of
Jahromi et al30 and Furst and Rodarte.31 In the present
study, dexamethasone did not significantly lessen
PONV for 5 days postoperatively (P > .05). Although
there was a statistically relevant difference in nausea
on the second postoperative day, the clinical differ-
ence was not important, because the need for anti-
emetics was low in the 2 groups (Table 1).
In this study, patients who received dexamethasone
required considerably more insulin compared with
patients who did not receive dexamethasone. In this
study, the glucose level was targeted to 5 to 8 mmol/Ln. Data are presented as means with 95% confidence limits. DEX,
, patients without dexamethasone.
axillofac Surg 2018.
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FIGURE 3. Serum or plasma lactate levels after microvascular reconstruction. Data are presented as means with 95% confidence limits. DEX,
patients with dexamethasone; NON-DEX, patients without dexamethasone. Q7
Kainulainen et al. Dexamethasone and Postoperative Recovery. J Oral Maxillofac Surg 2018.
p
ri
n
t
&
w
e
b
4
C
=
F
P
O
6 DEXAMETHASONE AND POSTOPERATIVE RECOVERY
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652and was maintained within these limits with insulin
infusions. The authors recorded the total amount of
insulin needed but did not collect the data on blood
glucose levels. The authors considered this the best
method to reflect glucose balance in this setting. The
effects of corticosteroids on glucose balance are well
known. A multicenter randomized double-blinded
placebo-controlled trial of 4,494 patients undergoing
cardiac surgery with cardiopulmonary bypass by
Dieleman et al32 showed that dexamethasone was
associated with higher postoperative glucose levels
and that dexamethasone use did not provide patient
benefit. The present study showed that accurate
glucose monitoring is needed for at least 5 days afterFIGURE 4. Serum CRP levels after microvascular reconstruction. Data a
protein; DEX, patients with dexamethasone; NON-DEX, patients without d
Kainulainen et al. Dexamethasone and Postoperative Recovery. J Oral M
FLA 5.5.0 DTD  YJOMS58278_proof surgery, because the need for insulin increases consid-
erably owing to the effect of dexamethasone on
glucose metabolism.
Major surgery causes a stress reaction, which can
contribute to anaerobic metabolism and inadequacy
of tissue perfusion, leading to increased lactate levels.
An association between increased lactate levels and
increased morbidity and mortality has been shown in
many studies.33,34 Patients in the DEX group had
statistically significantly higher lactate levels for
3 days postoperatively (P < .001). An increase in
lactate levels could be related to increased glucose
levels as mentioned by Ottens et al35 in their prospec-
tive trial. This increase will automatically lead to anre presented as means with 95% confidence limits. CRP, C-reactive
examethasone.
axillofac Surg 2018.
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FIGURE 5. Serum leukocyte levels after microvascular reconstruction. Data are presented as means with 95% confidence limits. DEX, patients
with dexamethasone; NON-DEX, patients without dexamethasone.
Kainulainen et al. Dexamethasone and Postoperative Recovery. J Oral Maxillofac Surg 2018.
KAINULAINEN ET AL 7
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784increased amount of insulin, as seen in the present
study. Although lactate levels were statistically higher
in patients in the DEX group, the levels were relatively
low (0 to 2.2 mmol/L) and within normal limits.
Lactate was not a prognostic factor in this study
when considering immediate recovery.
Trauma and surgery change blood counts. GCs
decrease the systemic inflammatory response caused
by surgical trauma. Use of preoperative and perioper-
ative GCs is associated with postoperative leukocy-
tosis and lower CRP levels.36,37 Postoperative
leukocyte and CRP concentrations are useful
markers of the magnitude of operative injury.38,39 In
the present study, CRP levels also were considerably
lower and leukocyte counts were markedly higher as
was expected in patients receiving dexamethasone.
In particular, the low CRP values (caused by
dexamethasone) might cause doctors to overlook
early-onset infections.
Despite being the largest prospective randomized
double-blinded trial of patients with reconstructive
surgery for head and neck cancer and perioperative
use of dexamethasone, the total number of patients
could have been larger. However, the number of
patients undergoing complex ablative and reconstruc-
tive surgery is limited even in a tertiary university cen-
ter. The present results have already decreased the
perioperative use of dexamethasone in reconstructive
head and neck cancer surgery in Finland.
In this study, the only benefit of perioperative dexa-
methasone use was the lower total dose of oxycodone.
However, the disadvantages were greater; these
included the need for increased insulin, disturbed
sugar metabolism, higher lactate levels, and
misleading CRP values. Dexamethasone is used quite
liberally in reconstructive head and neck surgery.FLA 5.5.0 DTD  YJOMS58278_proof The use of perioperative dexamethasone in patients
head and neck cancer and microvascular reconstruc-
tion seems to increase the risk of postoperative
infection.20 Although dexamethasone decreases post-
operative pain, the routine use of dexamethasone is
not justified in this patient group because it does not
seem to meaningfully decrease nausea, hasten rehabil-
itation, or shorten ICU or hospital stay. QReferences
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